Diarrhea Due to Clostridium Difficile
Conditions
Keywords
Clostridium difficile, recurrence, relapse, antibodies, immune response, prognosis
Brief summary
Clostridium difficile is responsible for up to 25% of reported antibiotic associated diarrhea cases and virtually all cases of pseudomembranous colitis (PMC). The clinical spectrum of C. difficile infection (CDI) varies in severity from asymptomatic carriage to self-limited, mild, watery diarrhea, to PMC, intestinal perforation, toxic megacolon, sepsis, fulminant colitis, and death. In the past decade, the 027/NAP1/BI strain has emerged world-wide and has been implicated in large outbreaks with increased severity, frequent recurrence, and significant mortality. The host immune responses can influence the severity of CDI and play crucial roles in CDI onset, progression, and overall prognosis. Low serum concentrations of antibodies directed against the toxins A&B of C. difficile have been associated with a higher risk of recurrence. However, there are conflicting reports.
Interventions
BIOLOGICALBlood sampling
Blood samples of 10 mL will be performed every 2 days from the first symptoms of CDI and until clinical recovery and/or hospital discharge
Sponsors
Hospices Civils de Lyon
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Hospitalized * Suffering from diarrhea related to C. difficile * Confirmed diagnosis of CDI * Informed consent by the patient * Affiliated to the social security regime
Exclusion criteria
* Out-patient * No confirmed diagnosis of CDI * Decline of participation * Patient not affiliated to the social security regime
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| immune response rate | up to 60 days after diagnosis |
Countries
France
Outcome results
None listed